Maraviroc

Generic Name
Maraviroc
Brand Names
Celsentri, Selzentry
Drug Type
Small Molecule
Chemical Formula
C29H41F2N5O
CAS Number
376348-65-1
Unique Ingredient Identifier
MD6P741W8A
Background

Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was ...

Indication

Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.

Associated Conditions
CCR5-tropic Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
-
Clinical Trials
Related News

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

First Posted Date
2012-01-06
Last Posted Date
2021-11-05
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
594
Registration Number
NCT01505114
Locations
🇺🇸

Weill Cornell Chelsea CRS, New York, New York, United States

🇺🇸

New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States

🇺🇸

UCLA CARE Center CRS, Los Angeles, California, United States

and more 10 locations

A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)

First Posted Date
2011-10-07
Last Posted Date
2019-02-27
Lead Sponsor
Bruce Brew
Target Recruit Count
19
Registration Number
NCT01449006
Locations
🇦🇺

St. Vincent's Hospital, Sydney, New South Wales, Australia

🇦🇺

The Alfred Hospital, Melbourne, Victoria, Australia

Safety Study of Maraviroc's Effect on Human Osteoclasts

Completed
Conditions
AIDS
HIV Infections
Interventions
Drug: Maraviroc
First Posted Date
2011-09-05
Last Posted Date
2014-09-25
Lead Sponsor
National Center for Global Health and Medicine, Japan
Target Recruit Count
16
Registration Number
NCT01428986
Locations
🇯🇵

National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

First Posted Date
2011-07-22
Last Posted Date
2024-10-11
Lead Sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Target Recruit Count
262
Registration Number
NCT01400412
Locations
🇺🇸

University of Colorado Hospital CRS (6101), Aurora, Colorado, United States

🇺🇸

Univ. of South Florida (USF) College of Medicine ATN CRS (33001), Tampa, Florida, United States

🇺🇸

Washington U CRS (2101), Saint Louis, Missouri, United States

and more 35 locations

Maraviroc Abacavir STudy - Effect on Endothelial Recovery

Phase 4
Conditions
Endothelial Dysfunction
Interventions
Drug: Maraviroc
First Posted Date
2011-07-07
Last Posted Date
2013-12-18
Lead Sponsor
S.F.L. van Lelyveld
Target Recruit Count
24
Registration Number
NCT01389063
Locations
🇳🇱

University Medical Center Utrecht, Utrecht, Netherlands

Maraviroc Switch Collaborative Study

Phase 4
Completed
Conditions
HIV
Interventions
Drug: Maraviroc
First Posted Date
2011-06-29
Last Posted Date
2016-01-20
Lead Sponsor
Kirby Institute
Target Recruit Count
399
Registration Number
NCT01384682
Locations
🇦🇷

Fundacion IDEAA, Buenos Aires, Argentina

🇦🇷

Hospital Privado- Centro Medico Cordoba, Cordoba, Argentina

🇦🇺

Holdsworth House Medical Practice, Sydney, New South Wales, Australia

and more 48 locations

The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study

Phase 1
Completed
Conditions
HIV
Interventions
Drug: Maraviroc
Drug: Truvada
Drug: Darunavir
First Posted Date
2011-05-05
Last Posted Date
2019-10-31
Lead Sponsor
Imperial College London
Target Recruit Count
13
Registration Number
NCT01348763
Locations
🇬🇧

Imperial College Healthcare NHS Trust, London, United Kingdom

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1

First Posted Date
2011-05-02
Last Posted Date
2016-01-14
Lead Sponsor
ViiV Healthcare
Target Recruit Count
813
Registration Number
NCT01345630
Locations
🇺🇸

Circle CARE Center, Norwalk, Connecticut, United States

🇫🇷

CHU de Nantes - Hotel Dieu, Nantes, France

🇺🇸

Health Services Center, Hobson City, Alabama, United States

and more 171 locations

A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B

Phase 4
Completed
Conditions
HIV Coinfection
Interventions
Drug: Placebo
Drug: Maraviroc
First Posted Date
2011-04-01
Last Posted Date
2017-12-06
Lead Sponsor
ViiV Healthcare
Target Recruit Count
138
Registration Number
NCT01327547
Locations
🇺🇸

AIDS Research Alliance, Los Angeles, California, United States

🇺🇸

Georgia Regents Medical Center, Augusta, Georgia, United States

🇺🇸

Saint Michael's Medical Center, Newark, New Jersey, United States

and more 45 locations

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

First Posted Date
2011-02-04
Last Posted Date
2011-06-29
Lead Sponsor
ViiV Healthcare
Target Recruit Count
28
Registration Number
NCT01290211
Locations
🇧🇪

Pfizer Investigational Site, Bruxelles, Belgium

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy